Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Vivus gets rights to two PAH candidates from Selten

Executive Summary

Selten Pharma Inc. licensed Vivus Inc. exclusive global rights to develop and commercialize tacrolimus (SPI026) and ascomycin (SPI054) for treating pulmonary arterial hypertension and related vascular diseases.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register